Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

GenFleet Closes $16 Million B+ Round for China-US Clinical Trials

publication date: Jan 29, 2021

GenFleet Therapeutics (Shanghai) closed a $16 million Series B+ round for clinical trials of its two lead oncology candidates in China and the US. The company completed a $57 million B financing in March, 2020. Founded in 2017, GenFleet develops first-in-class large and small therapeutic molecules for oncology and immunology targets. The B+ financing was led by Northern Light Venture Capital, with participation from HM Capital, Linden Asset Group, Shanjin Capital and existing investors. The company's A round was led by Ally Bridge. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital